Tempest Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Tempest Therapeutics

03/11/2023 14:59

* Tempest Therapeutics Inc  TPST.OQ   TPST.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Tempest
Therapeutics Inc
is for a loss of 57 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $10​, above​ its last closing price
of $3.84. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.55       -0.52      -0.54     Missed  -4.3
 Mar. 31 2023  -0.65       -0.64      -0.55     Beat    14.4
 Dec. 31 2022              -0.76      -0.63     Beat    17​
 Sep. 30 2022  -0.81       -0.80      -0.66     Beat    17.8
 ​​Jun.        -0.93       -0.92      -0.79     Beat    14.4
 30 2022                                                
 Mar. 31 2022  -1.12       -1.12      -1.18     Missed  -5.7​
 Dec. 31 2021              -1.23      -1.12     Beat    9.1
 Sep. 30 2021  -1.04       -1.05      -1.21     Missed  -15.6
 This summary was machine generated November 3 at 14:59 GMT.  All
figures in US dollars  unless otherwise stated